241 related articles for article (PubMed ID: 22325421)
1. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.
Payen MC; De Wit S; Martin C; Sergysels R; Muylle I; Van Laethem Y; Clumeck N
Int J Tuberc Lung Dis; 2012 Apr; 16(4):558-60. PubMed ID: 22325421
[TBL] [Abstract][Full Text] [Related]
2. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.
Dauby N; Muylle I; Mouchet F; Sergysels R; Payen MC
Pediatr Infect Dis J; 2011 Sep; 30(9):812-3. PubMed ID: 21378593
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
De Lorenzo S; Alffenaar JW; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Bolhuis MS; van Altena R; Viggiani P; Piana A; Spanevello A; Migliori GB
Eur Respir J; 2013 Jun; 41(6):1386-92. PubMed ID: 22997218
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
5. First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina.
Palmero D; González Montaner P; Cufré M; García A; Vescovo M; Poggi S
Arch Bronconeumol; 2015 Oct; 51(10):e49-52. PubMed ID: 26026689
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S; Payen MC; Sotgiu G; D'Ambrosio L; Alarcon Guizado V; Alffenaar JW; Abdo Arbex M; Caminero JA; Centis R; De Lorenzo S; Gaga M; Gualano G; Roby Arias AJ; Scardigli A; Skrahina A; Solovic I; Sulis G; Tadolini M; Akkerman OW; Alarcon Arrascue E; Aleska A; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2016 Apr; 47(4):1235-43. PubMed ID: 26965290
[TBL] [Abstract][Full Text] [Related]
7. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
Gonzalo X; Drobniewski F
J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
[TBL] [Abstract][Full Text] [Related]
8. Extensively drug-resistant tuberculosis in california, 1993-2006.
Banerjee R; Allen J; Westenhouse J; Oh P; Elms W; Desmond E; Nitta A; Royce S; Flood J
Clin Infect Dis; 2008 Aug; 47(4):450-7. PubMed ID: 18616396
[TBL] [Abstract][Full Text] [Related]
9. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran.
Tabarsi P; Chitsaz E; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Amiri M; Mansouri D; Masjedi MR; Velayati AA; Caminero JA
Microb Drug Resist; 2010 Mar; 16(1):81-6. PubMed ID: 20192820
[TBL] [Abstract][Full Text] [Related]
10. Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases.
Payen MC; Muylle I; Vandenberg O; Mathys V; Delforge M; Van den Wijngaert S; Clumeck N; De Wit S
Int J Tuberc Lung Dis; 2018 Jan; 22(1):34-39. PubMed ID: 29297423
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
12. Extensively drug-resistant (XDR) tuberculosis: an old and new threat.
Fattorini L; Migliori GB; Cassone A
Ann Ist Super Sanita; 2007; 43(4):317-9. PubMed ID: 18209265
[TBL] [Abstract][Full Text] [Related]
13. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S; Sotgiu G; D'Ambrosio L; Centis R; Abdo Arbex M; Alarcon Arrascue E; Alffenaar JW; Caminero JA; Gaga M; Gualano G; Skrahina A; Solovic I; Sulis G; Tadolini M; Alarcon Guizado V; De Lorenzo S; Roby Arias AJ; Scardigli A; Akkerman OW; Aleksa A; Artsukevich J; Auchynka V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Payen MC; Piana A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2016 Jun; 47(6):1758-66. PubMed ID: 27076583
[TBL] [Abstract][Full Text] [Related]
14. Drug susceptibility profile of Mycobacterium tuberculosis isolated from HIV infected and uninfected pulmonary tuberculosis patients in eastern India.
Chakraborty N; De C; Bhattacharyya S; Mukherjee A; Santra S; Banerjee D; Sarkar RN; Guha SK
Trans R Soc Trop Med Hyg; 2010 Mar; 104(3):195-201. PubMed ID: 19828165
[TBL] [Abstract][Full Text] [Related]
15. Extensively drug-resistant tuberculosis: experience at the Tuberculosis Research Centre, Chennai, India.
Thomas A; Joseph P; Nair D; Rao DV; Rekha VV; Selvakumar N; Jaggarajamma K; Balambal R
Int J Tuberc Lung Dis; 2011 Oct; 15(10):1323-5. PubMed ID: 22283888
[TBL] [Abstract][Full Text] [Related]
16. Treatment of extensively drug-resistant tuberculosis and role of the pharmacist.
Mitrzyk BM
Pharmacotherapy; 2008 Oct; 28(10):1243-54. PubMed ID: 18823220
[TBL] [Abstract][Full Text] [Related]
17. Meropenem-clavulanate: a new strategy for the treatment of tuberculosis?
Holzgrabe U
ChemMedChem; 2009 Jul; 4(7):1051-3. PubMed ID: 19462395
[TBL] [Abstract][Full Text] [Related]
18. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
[TBL] [Abstract][Full Text] [Related]
19. Extensively drug-resistant tuberculosis: new strains, new challenges.
Banerjee R; Schecter GF; Flood J; Porco TC
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):713-24. PubMed ID: 18847407
[TBL] [Abstract][Full Text] [Related]
20. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan.
Lai CC; Tan CK; Huang YT; Chou CH; Hung CC; Yang PC; Luh KT; Hsueh PR
Clin Infect Dis; 2008 Oct; 47(7):e57-63. PubMed ID: 18715157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
